Poly Medicure FY26 revenue rises 12.3%; net profit declines 5.3%
NiveshIQ
NSE: POLYMED · Healthcare
Poly Medicure Ltd.
₹1,738.50▼ ₹9.20 (-0.53%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on POLYMED. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Poly Medicure Ltd.
Poly Medicure Limited is a diversified medical device manufacturer headquartered in India, producing infusion therapy, critical care, dialysis, and cardiology products for both domestic and international markets. In FY26, the company reported a 12.3% rise in revenue to ₹1,997 crore, while net profit fell 5.3% to ₹315 crore, reflecting margin pressure amid competitive pricing. Recent strategic initiatives include a partnership with INS and the Infusion Nursing Society to launch the PACE clinical excellence program, aimed at expanding market penetration and strengthening brand credibility. Poly Medicure’s competitive position is bolstered by a broad product portfolio and strong distribution network, yet it faces stiff competition from both domestic players like Dr. Reddy’s and global entrant
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,376 Cr +132.40% | ₹1,670 Cr +21.40% | ₹1,875 Cr +12.30% |
| EBITDA Margin | 25.94% | 32.46% | 29.99% |
| Net Profit | ₹258.00 Cr +136.70% | ₹338.56 Cr +31.20% | ₹321.85 Cr -4.90% |
| EPS | ₹26.92 | – | ₹31.79 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Poly Medicure (NSE:POLYMED) in India's Medical Device Sector
INS partners with Poly Medicure to advance clinical excellence through PACE
🔒
+ 3 more stories about Poly Medicure Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹525 Cr, PAT ₹85 Cr, EPS ₹8.49, EBITDA margin 30.2%. Growth context: revenue YoY +1377.7%, PAT YoY +505.2%, revenue QoQ +19.2%, PAT QoQ -7.1%. Street verdict: strong beat, revenue surprise -0.2%, PAT surprise +18.7%.
Recent corporate activity highlights R&D investments and technology initiatives as the primary near-term growth lever, w...
FY26 (last completed FY): revenue ₹1, 875 Cr, PAT ₹322 Cr, EBITDA margin 30.0%, EPS ₹31.79. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for POLYMED
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track POLYMED alongside your other holdings
Unlock full POLYMED research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Poly Medicure Ltd.?
NiveshIQ detects active intelligence signals for Poly Medicure Ltd. (POLYMED) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Poly Medicure Ltd.?
Poly Medicure Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,621,845.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.